Advertisement

Topics

Genzyme Company Profile

00:42 EST 23rd November 2017 | BioPortfolio

Genzyme is one of the world’s leading biotechnology companies. Its more than 9,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases. Since its founding in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 2006 revenues of $3.2 billion. Over the past two decades Genzyme has introduced a number of breakthrough treatments in several areas of medicine, which have provided hope to patients who previously had no viable treatment options. Genzyme products are helping patients in nearly 90 countries. Today, Genzyme continues to be driven by its commitment to patients. The company is working to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments. Genzyme, which has its headquarters in Cambridge, Massachusetts, was selected by FORTUNE as one of the “100 Best Companies to Work for” in the United States in 2006 and 2007.

Location

500 Kendall Street
Cambridge
MA
02142
United States of America

Contact

Phone: 617 252 7500
Fax: 617 252 7600


News Articles [85 Associated News Articles listed on BioPortfolio]

STAT Plus: New chief aims to remake Sanofi Genzyme

Sanofi Genzyme's new president, Bill Sibold, is the first one without any ties to the old Genzyme, which pioneered the rare-disease business model.

Genzyme Stock, PTV News: May 07, 2010

Genzyme Board approves US $2B stock repurchase and considers options for 3 divisions

Genzyme: What Makes a Great Rare Disease Company.

In this episode of PharmaTelevision News Review, filmed at #BIO2012 Convention in Boston, Fintan Walton talks to David Meeker, President & CEO at Genzyme

Genzyme: Rogerio Vivaldi. Developing breakthrough therapies for uncommon and underserved medical conditions.

In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Rogerio Vivaldi from Genzyme

Genzyme Opts Out of Voyager Gene Therapy for Parkinson's Disease

Voyager Therapeutics said it will develop its lead candidate VY-AADC01 gene therapy for advanced Parkinson’s disease on its own, retaining full global rights, after Genzyme, a Sanofi company, o...

Genzyme Receives CF Discovery Grant

The Cystic Fibrosis Foundation has awarded Genzyme Corp. a $1.05 million grant for research to identify potential small-molecule drugs to treat cystic fibrosis...

Voyager Sinks as Sanofi Genzyme Opts Out of Parkinson's Gene Therapy Program

Shares of Voyager have fallen more than 12 percent in premarket trading after the company announced Sanofi Genzyme walked away from its $845M gene therapy treatment for Parkinson’s disease.

News Headlines, PTV News: Feb 12, 2010

Gaucher rivals: Genzyme set to lose blockbuster monopoly Generics- no thanks: AstraZeneca chief bucks copy-cat trendGaucher rivals: Genzyme set to lose blockbuster monopoly[RELEASED 10:30 am GMT]

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Cerezyme [Genzyme Corporation]

Thyrogen [Genzyme Corporation]

Renagel [Genzyme Corporation]

These highlights do not include all the information needed to use Renagel safely and effectively. See full prescribing information for Renagel. Renagel (sevelamer hydrochloride) Tablet for Oral use In...

Aldurazyme [Genzyme Corporation]

These highlights do not include all the information needed to use ALDURAZYME safely and effectively. See full prescribing information for ALDURAZYME. ALDURAZYME (laronidase)Solution for intravenous in...

Carticel [Genzyme Corporation]

These highlights do not include all the information needed to use Carticel safely and effectively. See full prescribing information for Carticel. Carticel® (autologous cultured chondrocytes) For Auto...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant.

Graft-versus-host disease (GVHD) is a leading cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (alloHCT). Prophylactic in-vivo T-Cell depletion with antithymocyte...

Clinical Trials [20 Associated Clinical Trials listed on BioPortfolio]

A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)

The purpose of this research study is to compare subject comfort during and after injection with NADGL and Captique® Injectable Gel, in the nasolabial folds. Captique® is an FDA-approve...

Extension Study of Long-Term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.

This extension study was to monitor the long-term safety and efficacy of rhGAA treatment in a single patient with infantile-onset Pompe disease who were previously treated with rhGAA in a ...

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

This open-label, rater-blinded extension study will enroll patients who have relapsing-remitting multiple sclerosis (RRMS) and who participated in one of three prior Genzyme-sponsored stud...

A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)

This study is sponsored by Genzyme Japan K.K. The purpose of this study is to assess the safety, tolerability and pharmacokinetics of Clofarabine (JC0707) intravenously administered to Jap...

Comparison of ATG to Thymoglobuline in Renal Transplantation

An open, multicenter, randomised, parallel group pilot study to investigate two different polyclonal rabbit immunoglobulin preparations for safety and efficacy: A comparison of ATG-Freseni...

Companies [20 Associated Companies listed on BioPortfolio]

Genzyme

Genzyme is one of the world’s leading biotechnology companies. Its more than 9,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact o...

Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals t...

Genzyme Corp.

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company ha...

Genzyme Genetics

Genzyme Genetics is a leading worldwide provider of reproductive and oncology diagnostic testing, as well as genetic counseling services. As a business unit of Genzyme Corporation, Genzyme Genetics em...

Genzyme Corporation

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company ha...

More Information about "Genzyme" on BioPortfolio

We have published hundreds of Genzyme news stories on BioPortfolio along with dozens of Genzyme Clinical Trials and PubMed Articles about Genzyme for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genzyme Companies in our database. You can also find out about relevant Genzyme Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...


Corporate Database Quicklinks



Searches Linking to this Company Record